GlassScriptPhysician profile
Anil K Dhuna
NPI 1912019118
$3,411.59
in general payments reported to CMS, 2019-2025
30 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $98.01 · 2021: $167 · 2022: $746 · 2023: $921 · 2024: $619 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $918.81 | 2022-2025 | Inspire |
| Sk Life Science, INC. | $265.07 | 2021-2024 | Xcopri |
| Biogen, INC. | $216.10 | 2021-2024 | Vumerity |
| Lundbeck LLC | $215.94 | 2019-2024 | Vyepti |
| Abbvie INC. | $211.26 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $196.32 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $187.21 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $139.17 | 2022 | |
| Allergan, INC. | $136.76 | 2019-2020 | |
| Celgene Corporation | $116.90 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $92.08 | 2024 | Zeposia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.63 | 2023 | Lifevest |
| Jazz Pharmaceuticals INC. | $72.79 | 2020-2024 | |
| Abbott Laboratories | $69.70 | 2024-2025 | Infinity |
| Itamar Medical INC | $62.15 | 2023 | Watchpatone |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.28 | 2025 | Hyqvia |
| Argenx US, INC. | $48.05 | 2023-2025 | Vyvgart Hytrulo |
| Livanova USA, INC. | $47.07 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $43.28 | 2024 | Nuplazid |
| Emd Serono, INC. | $34.24 | 2020-2025 | |
| Axsome Therapeutics, INC. | $28.70 | 2023 | Sunosi |
| Eisai INC. | $27.94 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.57 | 2022 | |
| Neurocrine Biosciences, INC. | $22.00 | 2024 | Ingrezza |
| Philips North America LLC | $19.59 | 2023 | |
| Harmony Biosciences LLC | $17.34 | 2023 | Wakix |
| Kyowa Kirin, INC. | $16.77 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.47 | 2022 | |
| Amgen INC. | $13.52 | 2020 | |
| Adamas Pharmaceuticals, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Dhuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.